Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint Versus Prespecified Ablation Strategy Followed by Cardioversion in Patients With Persistent Atrial Fibrillation

NCT05921734 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT05921734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05921734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study of Ablation Pursuing Atrial Fibrillation Termination as a Procedural Endpoint Versus Prespecified Ablation Strategy Followed by Cardioversion in Patients With Persistent Atrial Fibrillation
Lead sponsor
Shanghai Chest Hospital
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2023
Completion date
August 1, 2025
Enrollment
480 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, cathter ablation, endpoint